Amgen Drives Into Immunotherapy With Early Blinatumomab BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
Bispecific leukemia drug goes to FDA ahead of Phase III data in what could be a signature moment for the agency’s breakthrough designation program – and the company’s cancer deal-making.